PPT-Ibrutinib : First-in Class Inhibitor of BTK

Forms a specific and irreversible bond with cysteine481 in BTK Highly potent BTK inhibition at IC 50 05 nM Orally administered with once daily dosing resulting in 24hr target inhibition. The 100X Protease Inhibitor Cocktail is a clear colorless liquid Background In order to study speci64257c target proteins of interest proteasemediated degradation during the genera tion of protein lysates is to be avoided A loss of normal cellular c Ibrutinib. Sensitivity and Resistance in CLL. Y. Lynn Wang, MD, PhD, FCAP. Dept. of Pathology. University of Chicago. October 24, 2014. Outline. Ibrutinib. targets . in vivo CLL proliferation through . . lymfom. Från. indolent till aggressive . sjukdom. Del 1 . Birgitta. Sander . patologi. och . biologi. Del 2 Anna Laurell . klinik. och . terapi. MCL indolent till aggressive . sjukdom. Indolent. New agents timing?. Agne Paner, MD. Assistant professor of Medicine. RUSH University Medical Center. Blood Smear in CLL. Chronic Lymphocytic Leukemia. Most prevalent type of adult leukemia . 30% of all . Richard R. Furman, MD. CLL Research Center. BCR-associated Kinases:. Proven Effective Therapeutic Targets. Nat Rev Immunol 2:945. Syk (spleen tyrosine kinase. ):. fostamatinib. PRT062070. GS-9973. Btk (Bruton’s . RESONATE . (PCYC-1112) Trial of Ibrutinib Compared With Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Paul M. Barr, John C. Byrd,. . Jennifer . R. Brown. Overview. Overview (cont). Ibrutinib. -R. elated Cardiovascular A. E. s. Atrial Fibrillation. Ibrutinib-Related AF Data From 2016 ASH Conference. Wiczer et al Data. Risk Stratification. . Mechanisms of Ibrutinib-Related Cardiotoxicity. . A Brief Update of an Ongoing Trial. Jeff Jones, MD, MPH. 16 May 2015. 2. P. LYN. BCR. CD79a. CD79b. SYK. BTK. PLC. γ. IBRUTINIB. GROWTH. SURVIVAL. B-cell Receptor is the “Accelerator” of B-cells. Simon Rule. Professor of Clinical . Haematology. Consultant . Haematologist. Derriford. Hospital and Peninsula Medical School Plymouth. DISCLOSURES OF COMMERCIAL SUPPORT. Name of Company. Research support. Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP Clinical Pharmacy Specialist, Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas Panelist Matthew Snyder, PharmD, BCOP Evolving Treatment Strategies. for CLL/SLL and MCL. Beth Faiman PhD, MSN, APRN-BC, AOCN. Nurse Practitioner. Department of Hematology and Medical Oncology. Cleveland Clinic Taussig Cancer Institute. Cleveland, Ohio. enzyme inhibitors (ACE inhibitors). inhibit the conversion of angiotensin I to angiotensin II.. The. . main . indications of ACE inhibitors are shown below.. Heart Failure. ACE inhibitors are used in all grades of heart failure, . Josie . Montegaard. , MSN, AGPCNP-BC. Matthew S . Davids. , MD, . MMSc. . Disclosures for . Ms. . Montegaard. Advisory Committee . Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company . Consulting Agreements . Conflict of Interests. I declare NO relevant conflict of interests in:. Honoraria: . no. Consulting: . no. Research funding: . no. Advisory boards: . no. Patents e Royalties: . no. Discussing Off-label.